CD40 and autoimmune disease: Particularly, blocking the interaction between CD40 and CD40L by antibodies targeting CD40L was shown to be highly effective in treating autoimmune diseases; however, it also resulted in thrombotic events due to the targeting of CD40L on platelets, a potential life-threatening side effect that greatly restricted the utility of this therapeutic approach [15,16,17,18,19,20,21,22].